Between Jan 3 , 2011 , and March 6 , 2012 , we randomly assigned 324 eosinophilic individuals to placebo ( n = 80 ) or benralizumab 2 mg dose ( n = 81 ) , 20 mg dose , ( n = 81 ) , or 100 mg dose ( n = 82 ) , and 285 non-eosinophilic individuals to 100 mg benralizumab ( n = 142 , 140 included in analysis ) or placebo ( n = 143 , 142 included in analysis ) .